The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
Open accessAbstract
Adenosine receptors (ARs) function in the body’s response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A1AR activation or increasing the blood supply to heart muscle by the A2AAR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, nonalcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A3AR agonists are ongoing
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 4×
“Imaging Many adenosine derivatives that proved to be A2AAR-selective agonists have bulky, hydrophobic substitution at the C2 position of adenine (Jacobson and Gao, 2006).”
BackgroundInfluentialSelf-citationThe ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium
Eltzschig, H. K., Ibla, J. C., Furuta, G. T., Leonard, M. O., Jacobson, K. A., Enjyoji, K., Robson, S. C., & Colgan, S. P. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030891 · Cited by 499
Self-citationHeart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Pharmacological Activity and Clinical Use of PDRN
Squadrito, F., Bitto, A., Irrera, N., Pizzino, G., Pallio, G., Minutoli, L., & Altavilla, D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00224 · Cited by 215 · cited 1×
“Topically applied PDRN was in a clinical trial for reducing inflammation to promote wound healing in cases of diabetic foot ulcers (Squadrito et al., 2017).”
BackgroundSerchov, T., Clement, H.-W., Schwarz, M. K., Iasevoli, F., Tosh, D. K., Idzko, M., Jacobson, K. A., de Bartolomeis, A., Normann, C., Biber, K., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.07.010 · Cited by 210
Self-citation
Cited by
Pasquini, S., Contri, C., Cappello, M., Borea, P. A., Varani, K., & Vincenzi, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1030895 · Cited by 29
Adenosine Receptor Ligands as Potential Therapeutic Agents for Impaired Wound Healing and Fibrosis
Varano, F., Catarzi, D., Vigiani, E., Calenda, S., & Colotta, V. (2022) · Topics in Medicinal Chemistry · doi:10.1007/7355_2022_155 · Cited by 1
Metadata
- Authors
- Jacobson, K. A., Tosh, D. K., Jain, S., & Gao, Z.-G.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-03-28
- Volume
- 13
- Pages
- 124-124
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W2928555551
- Cited by
- 198
- References
- 6
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. https://app.cochat.ai/papers/10.3389/fncel.2019.00124
- The paper
- Jacobson, K. A., Tosh, D. K., Jain, S., & Gao, Z.-G. (2019). Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2019.00124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.